Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
Clinical Roundup

ECOG-ACRIN, Caris present breast cancer recurrence and risk stratification AI tools

December 12, 2025
Vol.51 No.45
Drugs & Targets

Caris, Ontada form collaboration to advance molecular research, cancer care

January 17, 2025
Vol.51 No.02
Drugs & Targets

FDA approves MI Cancer Seek as a CDx test for adults and pediatric patients

November 08, 2024
Vol.50 No.42
In Brief

ECOG-ACRIN, Caris collaborate on interrogating TAILORx breast cancer trial

October 25, 2024
Vol.50 No.40
Flatiron, Caris combine EHR, multi-omics data to support precision oncology
Real-world Evidence

Flatiron, Caris combine EHR, multi-omics data to support precision oncology

January 26, 2024
Vol.50 No.04
By Matthew Bin Han Ong
Drugs & Targets

Caris, Flatiron partner to create real-world data offering

January 12, 2024
Vol.50 No.02
Drugs & Targets

Caris and Xencor expand collaboration for XmAb antibody drug candidates

January 06, 2023
Vol.49 No.01
In Brief

Caris Life Sciences, Flatiron Health collaborate to increase access to comprehensive molecular testing

September 30, 2022
Vol.48 No.35

Trending Stories

  • HHS Secretary Kennedy’s diet advice is heavy on meat and light on scientific consensus
  • Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
  • Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
  • FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
    Draft guidance consolidates trial design updates for developers
  • “This is not about protecting life”: Supreme Court overturn of Roe v. Wade threatens lives of cancer patients, doctors
  • NCI slated to get a $9 million raise as Trump’s budget proposes about 10% cut for NIH

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account